These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 30930207)
41. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. Kaag M; Trost L; Thompson RH; Favaretto R; Elliott V; Shariat SF; Maschino A; Vertosick E; Raman JD; Dalbagni G BJU Int; 2014 Nov; 114(5):674-9. PubMed ID: 24314050 [TBL] [Abstract][Full Text] [Related]
42. Chemotherapy increases survival and downstaging of upper tract urothelial cancer. Davaro F; May A; McFerrin C; Raza SJ; Siddiqui S; Hamilton Z Can J Urol; 2019 Oct; 26(5):9938-9944. PubMed ID: 31629443 [TBL] [Abstract][Full Text] [Related]
43. An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database. Browne BM; Stensland KD; Moynihan MJ; Canes D Clin Genitourin Cancer; 2018 Aug; 16(4):e743-e750. PubMed ID: 29506950 [TBL] [Abstract][Full Text] [Related]
45. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Lane BR; Smith AK; Larson BT; Gong MC; Campbell SC; Raghavan D; Dreicer R; Hansel DE; Stephenson AJ Cancer; 2010 Jun; 116(12):2967-73. PubMed ID: 20564402 [TBL] [Abstract][Full Text] [Related]
47. Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A. Inokuchi J; Kuroiwa K; Kakehi Y; Sugimoto M; Tanigawa T; Fujimoto H; Gotoh M; Masumori N; Ogawa O; Eto M; Ohyama C; Yamaguchi A; Matsuyama H; Ichikawa T; Asano T; Mizusawa J; Eba J; Naito S World J Urol; 2017 Nov; 35(11):1737-1744. PubMed ID: 28508102 [TBL] [Abstract][Full Text] [Related]
48. The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. Lucca I; Kassouf W; Kapoor A; Fairey A; Rendon RA; Izawa JI; Black PC; Fajkovic H; Seitz C; Remzi M; Nyirády P; Rouprêt M; Margulis V; Lotan Y; de Martino M; Hofbauer SL; Karakiewicz PI; Briganti A; Novara G; Shariat SF; Klatte T BJU Int; 2015 Jul; 116(1):72-8. PubMed ID: 24825476 [TBL] [Abstract][Full Text] [Related]
49. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Gontero P; Van Rhijn BWG; Mostafid AH; Palou J; Shariat SF Eur Urol; 2018 Jan; 73(1):111-122. PubMed ID: 28867446 [TBL] [Abstract][Full Text] [Related]
50. Prognostic Value of Albumin/Globulin Ratio in Patients with Upper Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy. Fukushima H; Kobayashi M; Kawano K; Morimoto S Anticancer Res; 2018 Apr; 38(4):2329-2334. PubMed ID: 29599356 [TBL] [Abstract][Full Text] [Related]
51. [THE EFFICACY OF ENDOSCOPIC DUAL LASER TREATMENT FOR LOW GRADE UPPER TRACT UROTHELIAL CARCINOMA]. Shvero A; Zilberman DE; Laufer M; Dotan ZA; Ramon J; Winkler HZ; Kleinmann N Harefuah; 2020 Mar; 159(3):170-174. PubMed ID: 32186786 [TBL] [Abstract][Full Text] [Related]
52. Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Dominguez-Escrig JL; Peyronnet B; Seisen T; Bruins HM; Yuan CY; Babjuk M; Böhle A; Burger M; Compérat EM; Gontero P; Lam T; MacLennan S; Mostafid H; Palou J; van Rhijn BWG; Sylvester RJ; Zigeuner R; Shariat SF; Rouprêt M Eur Urol Focus; 2019 Mar; 5(2):224-241. PubMed ID: 29158169 [TBL] [Abstract][Full Text] [Related]
53. Advancements in the clinical management of upper tract urothelial carcinoma. Taylor J; Meng X; Ghandour R; Margulis V Expert Rev Anticancer Ther; 2019 Dec; 19(12):1051-1060. PubMed ID: 31770492 [No Abstract] [Full Text] [Related]
54. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. Shao IH; Lin YH; Hou CP; Juang HH; Chen CL; Chang PL; Tsui KH Drug Des Devel Ther; 2014; 8():1985-90. PubMed ID: 25364228 [TBL] [Abstract][Full Text] [Related]